Hunan Er-Kang Pharmaceutical Co., Ltd (300267.SZ)
CNY 2.44
(1.24%)
CNY 2.44
(1.24%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 691.6 Million CNY | -15.8% |
| 2022 | 821.34 Million CNY | 14.91% |
| 2021 | 714.77 Million CNY | -5.46% |
| 2020 | 756.05 Million CNY | -9.03% |
| 2019 | 831.09 Million CNY | -6.98% |
| 2018 | 893.48 Million CNY | 26.95% |
| 2017 | 703.78 Million CNY | -10.06% |
| 2016 | 782.48 Million CNY | 42.24% |
| 2015 | 550.1 Million CNY | 65.84% |
| 2014 | 331.71 Million CNY | 165.36% |
| 2013 | 125 Million CNY | 16.83% |
| 2012 | 106.99 Million CNY | 25.79% |
| 2011 | 85.06 Million CNY | 28.91% |
| 2010 | 65.98 Million CNY | 171.35% |
| 2009 | 24.31 Million CNY | 30.66% |
| 2008 | 18.61 Million CNY | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 701.29 Million CNY | 1.4% |
| 2024 Q3 | 648.34 Million CNY | -6.24% |
| 2024 Q2 | 691.48 Million CNY | -1.4% |
| 2023 Q2 | 829.66 Million CNY | -2.78% |
| 2023 Q3 | 731.11 Million CNY | -11.88% |
| 2023 FY | 691.6 Million CNY | -15.8% |
| 2023 Q1 | 853.41 Million CNY | 3.9% |
| 2023 Q4 | 691.6 Million CNY | -5.4% |
| 2022 Q2 | 826.99 Million CNY | 7.64% |
| 2022 FY | 821.34 Million CNY | 14.91% |
| 2022 Q4 | 821.34 Million CNY | -9.45% |
| 2022 Q3 | 907.05 Million CNY | 9.68% |
| 2022 Q1 | 768.32 Million CNY | 7.49% |
| 2021 Q1 | 785.35 Million CNY | 3.88% |
| 2021 Q3 | 792.38 Million CNY | -7.78% |
| 2021 Q4 | 714.77 Million CNY | -9.79% |
| 2021 Q2 | 859.2 Million CNY | 9.4% |
| 2021 FY | 714.77 Million CNY | -5.46% |
| 2020 Q4 | 756.05 Million CNY | -26.41% |
| 2020 Q1 | 967.13 Million CNY | 16.37% |
| 2020 FY | 756.05 Million CNY | -9.03% |
| 2020 Q3 | 1.02 Billion CNY | -10.55% |
| 2020 Q2 | 1.14 Billion CNY | 18.77% |
| 2019 Q1 | 943.28 Million CNY | 5.57% |
| 2019 FY | 831.09 Million CNY | -6.98% |
| 2019 Q4 | 831.09 Million CNY | -19.68% |
| 2019 Q3 | 1.03 Billion CNY | -0.1% |
| 2019 Q2 | 1.03 Billion CNY | 9.8% |
| 2018 Q1 | 789.17 Million CNY | 12.13% |
| 2018 Q2 | 863.71 Million CNY | 9.45% |
| 2018 Q4 | 893.48 Million CNY | -8.16% |
| 2018 Q3 | 972.83 Million CNY | 12.63% |
| 2018 FY | 893.48 Million CNY | 26.95% |
| 2017 Q3 | 1.04 Billion CNY | -12.22% |
| 2017 FY | 703.78 Million CNY | -10.06% |
| 2017 Q4 | 703.78 Million CNY | -32.76% |
| 2017 Q2 | 1.19 Billion CNY | -7.85% |
| 2017 Q1 | 1.29 Billion CNY | 65.35% |
| 2016 FY | 782.48 Million CNY | 42.24% |
| 2016 Q4 | 782.48 Million CNY | -17.15% |
| 2016 Q3 | 944.44 Million CNY | 10.3% |
| 2016 Q2 | 856.28 Million CNY | 12.11% |
| 2016 Q1 | 763.76 Million CNY | 38.84% |
| 2015 Q3 | 524.22 Million CNY | 6.85% |
| 2015 Q2 | 490.61 Million CNY | 15.73% |
| 2015 Q1 | 423.92 Million CNY | 27.8% |
| 2015 Q4 | 550.1 Million CNY | 4.94% |
| 2015 FY | 550.1 Million CNY | 65.84% |
| 2014 FY | 331.71 Million CNY | 165.36% |
| 2014 Q2 | 272.91 Million CNY | 32.91% |
| 2014 Q4 | 331.71 Million CNY | 17.99% |
| 2014 Q3 | 281.13 Million CNY | 3.01% |
| 2014 Q1 | 205.34 Million CNY | 64.27% |
| 2013 Q4 | 125 Million CNY | -24.56% |
| 2013 FY | 125 Million CNY | 16.83% |
| 2013 Q2 | 166.11 Million CNY | 22.32% |
| 2013 Q3 | 165.69 Million CNY | -0.25% |
| 2013 Q1 | 135.79 Million CNY | 26.92% |
| 2012 Q3 | 149.38 Million CNY | 21.67% |
| 2012 Q1 | 109.65 Million CNY | 28.9% |
| 2012 Q2 | 122.77 Million CNY | 11.97% |
| 2012 FY | 106.99 Million CNY | 25.79% |
| 2012 Q4 | 106.99 Million CNY | -28.37% |
| 2011 Q3 | 84.77 Million CNY | 5.17% |
| 2011 Q4 | 85.06 Million CNY | 0.35% |
| 2011 Q2 | 80.6 Million CNY | 0.0% |
| 2011 FY | 85.06 Million CNY | 28.91% |
| 2010 FY | 65.98 Million CNY | 171.35% |
| 2010 Q4 | 65.98 Million CNY | 0.0% |
| 2009 FY | 24.31 Million CNY | 30.66% |
| 2008 FY | 18.61 Million CNY | 0.0% |